Adjunctive vitamin d2 supplement in patient with allergen-specific immunotherapy randomized, double-blind, placebo-controlled trial
- Conditions
- Patients with allergic rhinitis and asthma begin treatment with allergen-specific immunotherapy.Calciferol, Vitamin D2 , allergic rhinitis, asthma, allergen-specific immunotherapy, TNSS score, ACT score, PEFR, Absolute eosinophil
- Registration Number
- TCTR20190813001
- Lead Sponsor
- Phramongkutklao Medicine Foundation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Enrolling by invitation
- Sex
- All
- Target Recruitment
- 30
1. Patients with allergic rhinitis and asthma.
2. Patients begin treatment with allergen-specific immunotherapy or Patients that used to treatment with allergen-specific immunotherapy and stop more than 6 months.
3. Patients decided to begin treatment with allergen-specific immunotherapy
4. Patient glad to join in this research and begin treatment with calciferol.
1. Patients were contrandicated to recieve Calciferol such as allergy.
2. Patients with liver or kidney disease
3. Patients with severe adverse effect from allergen-specfic immunotherapy or calciferol
4. Patients with 25-OH Vitamin D level above 150 ng/mL before start research.
5. Patients with severe or uncontrolled asthma
6. Patients with underlying active heart disease such as Myocardial infarction in 4 weeks.
7. Patients with active malignancy and on going treatment with chemotherapy.
8. Patients with primary and secondary immunodeficiency.
9. Patients were included in the previous research within 30 days.
10.Pregnancy patients at any GA.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical score TNSS, ACT, PEFR 10 weeks and 20 weeks Questionnaire
- Secondary Outcome Measures
Name Time Method aboratory Regulartory T cell, Absolute Eosinophil, IL-10, Der p 1-specific IgE and IgG4 levles 10 weeks and 20 weeks Blood drawing , flow cytometry, ELISA